SCHEMBL5094293

SCHEMBL5094293

CCOC(=O)/C=C(C(=C/O)/C(=O)OCC)\c1cccc(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.49
GAA P10253 1/20 0.49
NPSR1 Q6W5P4 1/20 0.44
XPO1 O14980 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 3/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ELANE P08246 1/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
PTGS2 P35354 1/20 0.38
TP53 P04637 1/20 0.38
CYP3A4 P08684 1/20 0.37
GRM5 P41594 1/20 0.37
KYAT1 Q16773 1/20 0.37
KCNK3 O14649 1/20 0.37
KCNK9 Q9NPC2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5094297 1.00 MAPT (0.49) MAPTGAANPSR1XPO1SMN1; SMN2
SCHEMBL5794078 0.84 MAPT (0.46) MAPTGAASMN1; SMN2LMNATDP1
SCHEMBL9501377 0.81 ELANE (0.42) MAPTGAASMN1; SMN2LMNAELANE
SCHEMBL12596917 0.78 LMNA (0.45) MAPTGAASMN1; SMN2LMNAELANE
SCHEMBL7682832 0.77 PARP1 (0.50) MAPTGAASMN1; SMN2LMNAELANE
SCHEMBL31749890 0.77 PARP1 (0.50) MAPTGAASMN1; SMN2LMNAELANE
SCHEMBL7682829 0.77 PARP1 (0.50) MAPTGAASMN1; SMN2LMNAELANE
SCHEMBL3018743 0.74 MAPT (0.51) MAPTGAAXPO1SMN1; SMN2LMNA
SCHEMBL21457358 0.73 ALDH1A1 (0.48) MAPTGAANPSR1SMN1; SMN2LMNA
SCHEMBL7055390 0.73 MAPT (0.47) MAPTGAANPSR1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7323570-B2 Farnesyltransferase inhibitors ABBOTT LABORATORIES (US) 2008-01-29 US disclosed
US-7211595-B2 Farnesyltransferase inhibitors ABBOTT LABORATORIES (US) 2007-05-01 US disclosed
US-20060264476-A1 Farnesyltransferase Inhibitors ABBVIE INC. 2006-11-23 US disclosed
EP-1339695-B1 FARNESYLTRANSFERASE INHIBITORS ABBOTT LAB (US) 2006-04-19 EP disclosed
US-20030087940-A1 Farnesyltransferase inhibitors ABBVIE INC. 2003-05-08 US disclosed
US-20020115640-A1 Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents ABBOTT LABORATORIES 2002-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115640-A1 Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents FNTB, FNTA, ACAT2 MAPT 2757/4885GAA 1267/4885NPSR1 4845/4885
US-20060264476-A1 Farnesyltransferase Inhibitors FNTB, FNTA, FDPS MAPT 2033/4885GAA 713/4885NPSR1 4749/4885
US-20030087940-A1 Farnesyltransferase inhibitors FNTB, FNTA, FDPS MAPT 2623/4885GAA 1082/4885NPSR1 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.